Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Depression Treatment Market Outlook (2022 to 2032)

[443 Pages Report] The global depression treatment market is set to exceed US$ 10.1 Billion in 2022, and expand at a CAGR of 5.2% to reach US$ 16.8 Billion by 2032. According to a recent study, drugs are the leading segment in terms of products and accounted for over 99.4% of the demand share in 2021.

Market Outlook:

Data Points Market Insights
Depression Treatment Market Value 2021 US$ 9.7 Billion
Market Value 2022 US$ 10.1 Billion
Market Value 2032 US$ 16.8 Billion
CAGR 2022 to 2032 5.2%
Market Share of Top 5 Countries 58.9%

The depression treatment market holds approximately 7.6% of the global behavioral health market worth US$ 128.2 Billion in 2021.

According to World Health Organization (WHO), the prevalence of mental health disorders and conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.

According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment.

Several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in the depression treatment market.

According to Future Market Insights (FMI), companies operating in the global depression treatment market are actively seeking to strengthen their position through mergers with established as well as emerging market players. For instance, in November 2020, Mylan completed a merger with Upjohn to form Viatris Company.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis Of Depression Treatment From 2012 To 2021 Vs Market Outlook For 2022 To 2032

As per FMI, the overall sales of depression treatment expanded at a CAGR of 3.4% from 2012 to 2021 owing to the increase in the prevalence of depression and anxiety disorders. Growth is also contributed to the growing need for antidepressants and therapies to treat mental conditions during the forecast period (2022 to 2032).

Depression treatments during a medical visit are time-consuming, and it is essential that people get treatment on time for depression. If conflicting demands continue to obstruct depression treatment, initiatives must ensure that patients with chronic physical difficulties receive high-quality mental healthcare in primary care.

According to a survey by the American Psychological Association (APA) in 2021, due to the pandemic, mental health issues are continuing to surge. Also, there has been a significant increase in demand for treatments for anxiety and depression compared to the last year.

Further, several new developments in antidepressants in the treatment of depression are being carried out in different drug classes, such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), antipsychotics, and others.

Depression Treatment Market

Recently, there has been a major shift in the market for depression disorders and other mental health disorder treatments. Numerous researchers and sponsors are developing novel drugs for the treatment of depression and getting approvals for them in different regions.

For instance, In September 2018, Alembic Pharmaceuticals received US FDA approval for its Desvenlafaxine ER capsules, 25 mg. A slew of these product launches and approvals of novel drugs and therapies in recent years is affecting the depression treatment market positively.

On the back of these aforementioned factors, sales in the depression treatment market are expected to increase at a CAGR of 5.2% from 2022 to 2032 globally.

What Are The Key Opportunities For Depression Treatment Market?

Governments are trying to increase the funding for mental health services and the treatment of mental illness and depression disorders.

The need for good quality treatments, affordable healthcare policies, funding of government organizations, and interventions of healthcare organizations for mental health disorders treatments are some of the factors boosting the market.

Rising demand for improved brain and mental fitness is opening up new avenues for depression treatments since they improve glucose metabolism in the brain and lower the risk of mental disorders.

Improving healthcare infrastructure and increasing medical expenditure by the governments will support the development of expensive drugs and expensive medical devices. Hence, the demand for depression treatment is expected to further increase over the next few years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Are The Factors Restraining Demand For Depression Treatment?

The non-availability and the limited number of such well-trained specialists can create an adverse impact on the treatment of patients with depression. Due to these factors, the quality of services can get affected, hampering the growth of the depression treatment market.

The release of generic equivalents to drugs used in the treatment of depression will soon provide the impetus for great total market expansion, resulting in a variety of low-cost prescription options for consumers.

As pharmaceutical companies lose their patent protection, certain products will face generic competition for the first time. The companies that designed the original products will face more competition due to this. Thus, patent expiry problems will hinder the growth of the depression treatment market.

For instance, Lexapro, which is used in the treatment of anxiety and depression, had a patent issue that expired on March 14, 2012.

There is a social stigma associated with depression and other mental diseases. Self-stigmatization makes patients feel ashamed and isolated, and it may hinder them from receiving effective therapy. It could also potentially lead to somatization. difficulty to comprehend for those who have never experienced it can be mistaken as a sign of weakness.

Country-Wise Insights

What Makes the USA the Largest Market for Depression Treatment?

Prevalence of Major Depressive Episodes (MDE) in the USA will Create Growth Prospects for Depression Treatment Market

The USA dominated the North American depression treatment market with a total share of about 92.8% in 2021 and is expected to experience the same growth throughout the forecast period owing to the rise in the prevalence of depressive disorders in the region.

According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had a major depressive episode with severe impairment.

Federal rules on drug launches and the availability of numerous branded formulations have a significant impact on market dynamics.

Why Germany is Considered a Lucrative Market for Depression Treatment in Europe?

Increasing Number of Depressive Disorders in Germany will Drive the Demand for Depression Treatment

According to FMI, Germany is set to exhibit a lucrative CAGR of 5.3% in the Europe depression treatment market during the forecast period (2022 to 2032).

As per the Institute for Health Metrics and Evaluation, Germany is having 3.7% of prevalence rate for depression disorders. Hence, the rising prevalence of depressive disorders in Germany will boost the market growth during the forecast period.

What Makes China an Emerging Market for Depression Treatment?

Improved Medical Infrastructure in China to Augment the Growth in Depression Treatment Market

China held a 43.4% market share in the East Asia depression treatment market in 2021 and is projected to increase at a CAGR rate of 4.8% during the forecast period. Growth is associated with rising healthcare costs and rapidly improving medical infrastructure is expected to drive the market during the forecast years.

According to Global Health Expenditure Database, the level of per capita health spending in 2020 is expected to be over 5,112 yuan, up from roughly 4,669 yuan the previous year.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which Product Type Will Gain Traction in Depression Treatment Market?

Drugs Contribute Over 99.4% of the Depression Treatment Market Sales

Based on products, the drugs segment will project a lucrative growth at a CAGR of 5.2% until 2032, with a market share of around 99.4% in 2021. Drugs are used as the first line of treatment during a depression treatment regime.

As compared to devices, drugs have a higher adoption rate and are cost-effective. TMS devices are commonly employed when other depression therapies have failed. In addition, the administration of drugs, which acts as antidepressants, improves the effectiveness of the treatment of depression without increasing the risk of clinically significant safety events, which makes it the most lucrative in depression treatment.

Which is the Leading Cause for Improving the Demand for Depression Treatment?

Rising Prevalence of Major Depression Episodes to Improve Depression Treatment Market Growth

Major depression held a revenue share of 53.5% in 2021 with a CAGR rate of 5.3%. The high market share is because major depression is highly being observed in the population over the world, which includes the symptoms such as anxiety, stress, mental illness, and others.

The high prevalence of major depression in the world is expected to contribute to enhancing market growth from 2022 to 2032.

Which Distribution Channel is Preferred for Depression Treatment Market?

Hospitals, in terms of distribution channels, led the depression treatment market with a 25.8% market share in 2021. During depression treatment, patients prefer to be admitted to the hospital to seek treatment.

The availability of highly skilled medical professionals that provide better treatment experience also contributed to the high market share during the coming years.

Competitive Landscape

Key players in the depression treatment market are focusing their efforts on acquisitions and expansion to move on with the development of a unique, first-in-class asset for the treatment of cognitive impairment caused by neuropsychiatric and neurodegenerative illnesses.

Given below are a few examples of the key strategies followed by the manufacturers:

  • In March 2022, AbbVie expanded its Neuroscience Portfolio with the acquisition of Syndesi Therapeutics.
  • In July 2020, Teva Pharmaceuticals decided new strategic focus on the Japanese Market. Japan’s business venture shifts focus to specialty assets and a portfolio of select generics that meet patients' medical needs.

Report Scope As Per Depression Treatment Industry Analysis

Attribute Details
Forecast Period 2012 to 2021
Historical Data Available for 2022 to 2032
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC countries, Turkey, South Africa, and North Africa.
Key Market Segments Covered Products, Diseases, Distribution Channels, and Regions
Key Companies Profiled
  • Viatris (Mylan Pharmaceuticals Inc.)
  • Sunovian Pharmaceuticals
  • AbbVie Inc. (Allergan, Inc.)
  • Jubilant Generics Limited
  • Sanis Health Inc.
  • Abbott Laboratories
  • Aurobindo Pharma
  • Torrent Pharmaceuticals
  • Teva Pharmaceuticals
  • Sun Pharmaceuticals
  • (Apotex Holdings, Inc.) Apotex Corporation
  • Alembic Pharmaceuticals Limited
  • Pfizer Inc.
  • Cardinal Health
  • Hikma Pharmaceuticals
  • Zydus Lifesciences (Cadila)
  • Cipla Ltd
  • Dr. Reddy's Laboratories
  • Merck & Co.
  • Eli Lily & Co
  • GlaxoSmithKline
  • Takeda Pharmaceuticals
  • BrainsWay Ltd.
  • Nexstim Plc
  • Magstim Ltd.
  • Neuronetics, Inc.
  • Salience TMS Neuro Solutions
  • MagVenture
  • MAG & More GmbH
  • Neurosoft, Ltd.
Pricing Available upon Request

Key Market Segments Covered In Depression Treatment Industry Research

By Products:

  • Drugs
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
      • Citalopram
      • Escitalopram
      • Fluoxetine
      • Fluvoxamine
      • Paroxetine
      • Sertraline
    • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
      • Desvenlafaxine succinate
      • Duloxetine
      • Levomilnacipran
      • Venlafaxine
    • Bupropion
    • Mirtazapine
    • Monoamine oxidase inhibitors (MAOIs)
      • Phenelzine
      • Tranylcypromine
    • Antipsychotics
      • Lithium carbonate
      • Aripiprazole
      • Brexipiprazole
      • Quetiapine
    • Trazodone
    • Others
  • TMS Devices
    • rTMS Devices
    • dTMS Devices

By Disease:

  • Major Depression
  • Persistent Depressive Disorder
  • Bipolar Disorder
  • Seasonal Affective Disorder (SAD)
  • Postpartum Depression
  • Premenstrual Dysphoric Disorder (PDD)
  • Situational Depression
  • Atypical Depression
  • Treatment-Resistant Depression

By Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • e-commerce
  • Specialty Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How much is the depression treatment market worth in 2021?

The global depression treatment market was worth US$ 9.7 Billion in 2021 and is set to expand 1.7X over the next ten years.

What is the sales forecast for depression treatment through 2032?

The depression treatment market is expected to reach US$ 16.8 Billion by the end of 2032, with sales revenue expected to register a growth of 5.2% CAGR.

What are the key trends shaping the Depression Treatment Market?

Adoption of different key strategies by market players and mergers and acquisitions by manufacturers are some of the key trends in the depression treatment market.

Which are the top 5 countries driving demand for Depression Treatment?

The USA, Germany, UK, India and China are expected to drive demand for the depression treatment industry.

What is North America Market Outlook for Depression Treatment?

North America is of the leading depression treatment market, with a market share of 40.3% in 2021 in the global market.

At what percentage is the demand for depression treatment expected to register growth in Europe?

Demand for depression treatment in Europe is expected to register a growth of 5.2% CAGR over the next ten years.

What was the last 9-year market CAGR for depression treatment?

From 2012 to 2021, the market for depression treatment expanded at the rate of 3.4%.

Which are the top 3 key players in the depression treatment market?

BrainsWay Ltd., Neuronetics, Inc., and Novartis are the Top 3 key players in the depression treatment market.

Table of Content

1. Executive Summary | Depression Treatment Market

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions & Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Innovation / Development Trends

4. Key Success Factors

    4.1. Disease Epidemiology, By Region

    4.2. Drug Adoption / Usage Analysis

    4.3. New Drug Approvals & Launches

    4.4. Key Promotional Strategies by Market Players

    4.5. Pipeline Analysis

    4.6. Regulatory Scenario

    4.7. PESTLE Analysis

    4.8. Porter’s Analysis

    4.9. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Market Outlook

        5.1.3. Global Mental Health Disorders Market Outlook

        5.1.4. Global Pharmaceutical Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Top Companies Historical Growth

        5.2.2. Product Adoption Rate and Demand

        5.2.3. Increasing burden of mental illnesses

        5.2.4. Availability of various therapies

        5.2.5. COVID-19 impact

        5.2.6. Technological Advancements in Equipment

        5.2.7. Increasing Demand for Depression Disorders Treatment

        5.2.8. New Product Launches

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

    6.1. Current COVID-19 Statistics and Probable Future Impact

    6.2. Current GDP Projection and Probable Impact

    6.3. COVID-19 and Impact Analysis

    6.4. 2021 Market Scenario

7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032

    7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021

    7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Product Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Product Type, 2012 to 2021

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032

        8.3.1. Drugs

            8.3.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)

                8.3.1.1.1. Citalopram

                8.3.1.1.2. Escitalopram

                8.3.1.1.3. Fluoxetine

                8.3.1.1.4. Fluvoxamine

                8.3.1.1.5. Paroxetine

                8.3.1.1.6. Sertraline

            8.3.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)

                8.3.1.2.1. Desvenlafaxine succinate

                8.3.1.2.2. Duloxetine

                8.3.1.2.3. Levomilnacipran

                8.3.1.2.4. Venlafaxine

            8.3.1.3. Bupropion

            8.3.1.4. Mirtazapine

            8.3.1.5. Monoamine oxidase inhibitors (MAOIs)

                8.3.1.5.1. Phenelzine

                8.3.1.5.2. Tranylcypromine

            8.3.1.6. Antipsychotics

                8.3.1.6.1. Lithium carbonate

                8.3.1.6.2. Aripiprazole

                8.3.1.6.3. Brexipiprazole

                8.3.1.6.4. Quetiapine

            8.3.1.7. Trazodone

            8.3.1.8. Others

        8.3.2. TMS Devices

            8.3.2.1. rTMS Devices

            8.3.2.2. dTMS Devices

    8.4. Market Attractiveness Analysis By Disease Type

9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Disease Type

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Disease Type, 2012 to 2021

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032

        9.3.1. Major Depression

        9.3.2. Persistent Depressive Disorder

        9.3.3. Bipolar Disorder

        9.3.4. Seasonal Affective Disorder (SAD)

        9.3.5. Postpartum Depression

        9.3.6. Premenstrual Dysphoric Disorder (PDD)

        9.3.7. Situational Depression

        9.3.8. Atypical Depression

        9.3.9. Treatment-Resistant Depression

    9.4. Market Attractiveness Analysis By Disease Type

10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2021

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel 2022 to 2032

        10.3.1. Hospitals

        10.3.2. Retail Pharmacies

        10.3.3. Drug Stores

        10.3.4. e-commerce

        10.3.5. Specialty Clinics

    10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Analysis, By Region, 2012 to 2021

    11.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. East Asia

        11.3.5. South Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa (MEA)

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        12.3.1. By Country

            12.3.1.1. United States of America

            12.3.1.2. Canada

        12.3.2. By Product Type

        12.3.3. By Disease Type

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Product Type

        12.4.3. By Disease Type

        12.4.4. By Distribution Channel

    12.5. Market Trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country-Level Analysis & Forecast

        12.8.1. USA Market

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Product Type

                12.8.1.2.2. By Disease Type

                12.8.1.2.3. By Distribution Channel

        12.8.2. Canada Market

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Product Type

                12.8.2.2.2. By Disease Type

                12.8.2.2.3. By Distribution Channel

13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Product Type

        13.3.3. By Disease Type

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Product Type

        13.4.3. By Disease Type

        13.4.4. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country-Level Analysis & Forecast

        13.8.1. Brazil Market

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Product Type

                13.8.1.2.2. By Disease Type

                13.8.1.2.3. By Distribution Channel

        13.8.2. Mexico Market

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Product Type

                13.8.2.2.2. By Disease Type

                13.8.2.2.3. By Distribution Channel

        13.8.3. Argentina Market

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Product Type

                13.8.3.2.2. By Disease Type

                13.8.3.2.3. By Distribution Channel

14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        14.3.1. By Country

            14.3.1.1. United Kingdom

            14.3.1.2. Germany

            14.3.1.3. Italy

            14.3.1.4. France

            14.3.1.5. Spain

            14.3.1.6. Russia

            14.3.1.7. BENELUX

            14.3.1.8. Rest of Europe

        14.3.2. By Product Type

        14.3.3. By Disease Type

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Product Type

        14.4.3. By Disease Type

        14.4.4. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country-Level Analysis & Forecast

        14.8.1. UK Market

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Product Type

                14.8.1.2.2. By Disease Type

                14.8.1.2.3. By Distribution Channel

        14.8.2. Germany Market

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Product Type

                14.8.2.2.2. By Disease Type

                14.8.2.2.3. By Distribution Channel

        14.8.3. Italy Market

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Product Type

                14.8.3.2.2. By Disease Type

                14.8.3.2.3. By Distribution Channel

        14.8.4. France Market

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Product Type

                14.8.4.2.2. By Disease Type

                14.8.4.2.3. By Distribution Channel

        14.8.5. Spain Market

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Product Type

                14.8.5.2.2. By Disease Type

                14.8.5.2.3. By Distribution Channel

        14.8.6. Russia Market

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Product Type

                14.8.6.2.2. By Disease Type

                14.8.6.2.3. By Distribution Channel

        14.8.7. BENELUX Market

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Disease Type

                14.8.7.2.2. By Product Type

                14.8.7.2.3. By Distribution Channel

15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Thailand

            15.3.1.3. Indonesia

            15.3.1.4. Malaysia

            15.3.1.5. Rest of South Asia

        15.3.2. By Product Type

        15.3.3. By Disease Type

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product Type

        15.4.3. By Disease Type

        15.4.4. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country-Level Analysis & Forecast

        15.8.1. India Market

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Product Type

                15.8.1.2.2. By Disease Type

                15.8.1.2.3. By Distribution Channel

        15.8.2. Thailand Market

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Product Type

                15.8.2.2.2. By Disease Type

                15.8.2.2.3. By Distribution Channel

        15.8.3. Indonesia Market

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Product Type

                15.8.3.2.2. By Disease Type

                15.8.3.2.3. By Distribution Channel

        15.8.4. Malaysia Market

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Product Type

                15.8.4.2.2. By Disease Type

                15.8.4.2.3. By Distribution Channel

16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    16.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Product Type

        16.3.3. By Disease Type

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product Type

        16.4.3. By Disease Type

        16.4.4. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country-Level Analysis & Forecast

        16.8.1. China Market

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Product Type

                16.8.1.2.2. By Disease Type

                16.8.1.2.3. By Distribution Channel

        16.8.2. Japan Market

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Product Type

                16.8.2.2.2. By Disease Type

                16.8.2.2.3. By Distribution Channel

        16.8.3. South Korea Market

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Product Type

                16.8.3.2.2. By Disease Type

                16.8.3.2.3. By Distribution Channel

17. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    17.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Product Type

        17.3.3. By Disease Type

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product Type

        17.4.3. By Disease Type

        17.4.4. By Distribution Channel

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country-Level Analysis & Forecast

        17.8.1. Australia Market

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Product Type

                17.8.1.2.2. By Disease Type

                17.8.1.2.3. By Distribution Channel

        17.8.2. New Zealand Market

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Product Type

                17.8.2.2.2. By Disease Type

                17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021

    18.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032

        18.3.1. By Country

            18.3.1.1. Turkey

            18.3.1.2. GCC Countries

            18.3.1.3. North Africa

            18.3.1.4. South Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Product Type

        18.3.3. By Disease Type

        18.3.4. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Product Type

        18.4.3. By Disease Type

        18.4.4. By Distribution Channel

    18.5. Market Trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country-Level Analysis & Forecast

        18.8.1. Turkey Market

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Product Type

                18.8.1.2.2. By Disease Type

                18.8.1.2.3. By Distribution Channel

        18.8.2. GCC Countries Market

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Product Type

                18.8.2.2.2. By Disease Type

                18.8.2.2.3. By Distribution Channel

        18.8.3. North Africa Market

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Product Type

                18.8.3.2.2. By Disease Type

                18.8.3.2.3. By Distribution Channel

        18.8.4. South Africa Market

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Product Type

                18.8.4.2.2. By Disease Type

                18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players

    19.3. Market Presence Analysis

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Technology Foot-Print, By Competition

    20.3. Competition Benchmarking

    20.4. Competition Deep Dive

        20.4.1. Viatris (Mylan Pharmaceuticals Inc.)

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. Key Financials

            20.4.1.4. SWOT Analysis

            20.4.1.5. Sales Footprint

            20.4.1.6. Strategy Overview

            20.4.1.7. Key Developments

        20.4.2. Sunovian Pharmaceuticals

            20.4.2.1. Overview

            20.4.2.2. Product Portfolio

            20.4.2.3. Key Financials

            20.4.2.4. SWOT Analysis

            20.4.2.5. Sales Footprint

            20.4.2.6. Strategy Overview

            20.4.2.7. Key Developments

        20.4.3. AbbVie Inc (Allergan, Inc.)

            20.4.3.1. Overview

            20.4.3.2. Product Portfolio

            20.4.3.3. Key Financials

            20.4.3.4. SWOT Analysis

            20.4.3.5. Sales Footprint

            20.4.3.6. Strategy Overview

            20.4.3.7. Key Developments

        20.4.4. Jubilant Generics Limited

            20.4.4.1. Overview

            20.4.4.2. Product Portfolio

            20.4.4.3. Key Financials

            20.4.4.4. SWOT Analysis

            20.4.4.5. Sales Footprint

            20.4.4.6. Strategy Overview

            20.4.4.7. Key Developments

        20.4.5. Sanis Health Inc

            20.4.5.1. Overview

            20.4.5.2. Product Portfolio

            20.4.5.3. Key Financials

            20.4.5.4. SWOT Analysis

            20.4.5.5. Sales Footprint

            20.4.5.6. Strategy Overview

            20.4.5.7. Key Developments

        20.4.6. Abbott Laboratories

            20.4.6.1. Overview

            20.4.6.2. Product Portfolio

            20.4.6.3. Key Financials

            20.4.6.4. SWOT Analysis

            20.4.6.5. Sales Footprint

            20.4.6.6. Strategy Overview

            20.4.6.7. Key Developments

        20.4.7. Aurobindo Pharma

            20.4.7.1. Overview

            20.4.7.2. Product Portfolio

            20.4.7.3. Key Financials

            20.4.7.4. SWOT Analysis

            20.4.7.5. Sales Footprint

            20.4.7.6. Strategy Overview

            20.4.7.7. Key Developments

        20.4.8. Torrent Pharmaceuticals

            20.4.8.1. Overview

            20.4.8.2. Product Portfolio

            20.4.8.3. Key Financials

            20.4.8.4. SWOT Analysis

            20.4.8.5. Sales Footprint

            20.4.8.6. Strategy Overview

            20.4.8.7. Key Developments

        20.4.9. Teva Pharmaceuticals

            20.4.9.1. Overview

            20.4.9.2. Product Portfolio

            20.4.9.3. Key Financials

            20.4.9.4. SWOT Analysis

            20.4.9.5. Sales Footprint

            20.4.9.6. Strategy Overview

            20.4.9.7. Key Developments

        20.4.10. Sun Pharmaceuticals

            20.4.10.1. Overview

            20.4.10.2. Product Portfolio

            20.4.10.3. Key Financials

            20.4.10.4. SWOT Analysis

            20.4.10.5. Sales Footprint

            20.4.10.6. Strategy Overview

            20.4.10.7. Key Developments

        20.4.11. (Apotex Holdings, Inc.) Apotex Corporation

            20.4.11.1. Overview

            20.4.11.2. Product Portfolio

            20.4.11.3. Key Financials

            20.4.11.4. SWOT Analysis

            20.4.11.5. Sales Footprint

            20.4.11.6. Strategy Overview

            20.4.11.7. Key Developments

        20.4.12. Alembic Pharmaceuticals Limited

            20.4.12.1. Overview

            20.4.12.2. Product Portfolio

            20.4.12.3. Key Financials

            20.4.12.4. SWOT Analysis

            20.4.12.5. Sales Footprint

            20.4.12.6. Strategy Overview

            20.4.12.7. Key Developments

        20.4.13. Pfizer Inc

            20.4.13.1. Overview

            20.4.13.2. Product Portfolio

            20.4.13.3. Key Financials

            20.4.13.4. SWOT Analysis

            20.4.13.5. Sales Footprint

            20.4.13.6. Strategy Overview

            20.4.13.7. Key Developments

        20.4.14. Cardinal Health

            20.4.14.1. Overview

            20.4.14.2. Product Portfolio

            20.4.14.3. Key Financials

            20.4.14.4. SWOT Analysis

            20.4.14.5. Sales Footprint

            20.4.14.6. Strategy Overview

            20.4.14.7. Key Developments

        20.4.15. Hikma Pharmaceuticals

            20.4.15.1. Overview

            20.4.15.2. Product Portfolio

            20.4.15.3. Key Financials

            20.4.15.4. SWOT Analysis

            20.4.15.5. Sales Footprint

            20.4.15.6. Strategy Overview

            20.4.15.7. Key Developments

        20.4.16. Zydus Lifesciences (Cadila)

            20.4.16.1. Overview

            20.4.16.2. Product Portfolio

            20.4.16.3. Key Financials

            20.4.16.4. SWOT Analysis

            20.4.16.5. Sales Footprint

            20.4.16.6. Strategy Overview

            20.4.16.7. Key Developments

        20.4.17. Cipla Ltd

            20.4.17.1. Overview

            20.4.17.2. Product Portfolio

            20.4.17.3. Key Financials

            20.4.17.4. SWOT Analysis

            20.4.17.5. Sales Footprint

            20.4.17.6. Strategy Overview

            20.4.17.7. Key Developments

        20.4.18. Dr. Reddy's Laboratories

            20.4.18.1. Overview

            20.4.18.2. Product Portfolio

            20.4.18.3. Key Financials

            20.4.18.4. SWOT Analysis

            20.4.18.5. Sales Footprint

            20.4.18.6. Strategy Overview

            20.4.18.7. Key Developments

        20.4.19. Merck & Co.

            20.4.19.1. Overview

            20.4.19.2. Product Portfolio

            20.4.19.3. Key Financials

            20.4.19.4. SWOT Analysis

            20.4.19.5. Sales Footprint

            20.4.19.6. Strategy Overview

            20.4.19.7. Key Developments

        20.4.20. Eli Lily & Co

            20.4.20.1. Overview

            20.4.20.2. Product Portfolio

            20.4.20.3. Key Financials

            20.4.20.4. SWOT Analysis

            20.4.20.5. Sales Footprint

            20.4.20.6. Strategy Overview

            20.4.20.7. Key Developments

        20.4.21. GlaxoSmithKline

            20.4.21.1. Overview

            20.4.21.2. Product Portfolio

            20.4.21.3. Key Financials

            20.4.21.4. SWOT Analysis

            20.4.21.5. Sales Footprint

            20.4.21.6. Strategy Overview

            20.4.21.7. Key Developments

        20.4.22. Takeda Pharmaceuticals

            20.4.22.1. Overview

            20.4.22.2. Product Portfolio

            20.4.22.3. Key Financials

            20.4.22.4. SWOT Analysis

            20.4.22.5. Sales Footprint

            20.4.22.6. Strategy Overview

            20.4.22.7. Key Developments

        20.4.23. BrainsWay Ltd.

            20.4.23.1. Overview

            20.4.23.2. Product Portfolio

            20.4.23.3. Key Financials

            20.4.23.4. SWOT Analysis

            20.4.23.5. Sales Footprint

            20.4.23.6. Strategy Overview

            20.4.23.7. Key Developments

        20.4.24. Nexstim Plc

            20.4.24.1. Overview

            20.4.24.2. Product Portfolio

            20.4.24.3. Key Financials

            20.4.24.4. SWOT Analysis

            20.4.24.5. Sales Footprint

            20.4.24.6. Strategy Overview

            20.4.24.7. Key Developments

        20.4.25. Magstim Ltd.

            20.4.25.1. Overview

            20.4.25.2. Product Portfolio

            20.4.25.3. Key Financials

            20.4.25.4. SWOT Analysis

            20.4.25.5. Sales Footprint

            20.4.25.6. Strategy Overview

            20.4.25.7. Key Developments

        20.4.26. Neuronetics, Inc.

            20.4.26.1. Overview

            20.4.26.2. Product Portfolio

            20.4.26.3. Key Financials

            20.4.26.4. SWOT Analysis

            20.4.26.5. Sales Footprint

            20.4.26.6. Strategy Overview

            20.4.26.7. Key Developments

        20.4.27. Salience TMS Neuro Solutions

            20.4.27.1. Overview

            20.4.27.2. Product Portfolio

            20.4.27.3. Key Financials

            20.4.27.4. SWOT Analysis

            20.4.27.5. Sales Footprint

            20.4.27.6. Strategy Overview

            20.4.27.7. Key Developments

        20.4.28. MagVenture

            20.4.28.1. Overview

            20.4.28.2. Product Portfolio

            20.4.28.3. Key Financials

            20.4.28.4. SWOT Analysis

            20.4.28.5. Sales Footprint

            20.4.28.6. Strategy Overview

            20.4.28.7. Key Developments

        20.4.29. MAG & More GmbH

            20.4.29.1. Overview

            20.4.29.2. Product Portfolio

            20.4.29.3. Key Financials

            20.4.29.4. SWOT Analysis

            20.4.29.5. Sales Footprint

            20.4.29.6. Strategy Overview

            20.4.29.7. Key Developments

        20.4.30. Neurosoft, Ltd.

            20.4.30.1. Overview

            20.4.30.2. Product Portfolio

            20.4.30.3. Key Financials

            20.4.30.4. SWOT Analysis

            20.4.30.5. Sales Footprint

            20.4.30.6. Strategy Overview

            20.4.30.7. Key Developments

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Postpartum Depression Management Market

Published : July 2022

Healthcare

Drug Free Depression Treatment Market

Published : April 2022

Explore Healthcare Insights

View Reports

Depression Treatment Market